With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.129779-30-2,(3R,5S)-rel-tert-Butyl 3,5-dimethylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
173 2-flH-Ihdazol-4-yl)-4-morpholin-4-yl-6-((2S.6R)-2A6-trimethyl-piperazin-l- ylmethylVthieno[3 ,2-dlpyrimidineTo (66) (1.5g) in ethanol (3OmL) was added sodium borohydride (Ig). After 4 h the reaction mixture was quenched with brine and the resulting solid was collected by filtration, and air dried to furnish 168 (2-chloro-4-morpholin-4-yl- thieno[3,2-d]pyrimidin-6-yl)-rnethanol (1.42g).To a solution of 168 (1.42g) in toluene (14ml), warmed to 400C, was added phosphorous tribromide (0.16ml). The resulting mixture was then heated to 1000C for 6 h, was cooled, diluted with chloroform, washed with brine, and dried (MgSO4). The solvent was removed in vacuo to yield 6-bromomethyl-2-chloro-4-morpholin-4- yl-thieno[3,2-d]pyrimidine, 169 (1.4Og). EPO
129779-30-2, The synthetic route of 129779-30-2 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; PIRAMED LIMITED; WO2006/46031; (2006); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics